Our serum FGF19 data consist to expressions of FGF19/FGFR4 and EpCAM in tissue distributions, and provide further evidence for FGF19 as a marker to evaluate the risk of HCC in patients with fatty liver disease. Here, FGF19 is linked to hepatocellular carcinoma.